68 related articles for article (PubMed ID: 28639280)
1. Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology.
Pfarr N; Darb-Esfahani S; Leichsenring J; Taube E; Boxberg M; Braicu I; Jesinghaus M; Penzel R; Endris V; Noske A; Weichert W; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Oct; 56(10):758-766. PubMed ID: 28639280
[TBL] [Abstract][Full Text] [Related]
2. Amplification of MDM2 and Loss of p16 Expression: Do They Have a Role in Malignant Transformation of Ovarian Brenner Tumor?
Wang L; Allison D; Shukla PS
Am J Clin Pathol; 2020 Jun; 154(1):133-141. PubMed ID: 32322877
[TBL] [Abstract][Full Text] [Related]
3. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
4. MDM2 amplification in malignant Brenner tumors may play a role in progression to malignancy and aid in separation from urothelial and other ovarian carcinomas.
Shetty S; Habeeb O; Rivera C; Astbury C; Przybycin C; Joehlin-Price AS
Hum Pathol; 2021 Nov; 117():42-50. PubMed ID: 34391746
[TBL] [Abstract][Full Text] [Related]
5. Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
Simons M; Simmer F; Bulten J; Ligtenberg MJ; Hollema H; van Vliet S; de Voer RM; Kamping EJ; van Essen DF; Ylstra B; Schwartz LE; Wang Y; Massuger LF; Nagtegaal ID; Kurman RJ
Mod Pathol; 2020 Apr; 33(4):722-733. PubMed ID: 31695154
[TBL] [Abstract][Full Text] [Related]
6. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.
Zheng L; Chen H; Zhao J; Roy-Chowdhuri S; Kamat AM; Alhalabi O; Gao J; Siefker-Radtke A; Hansel DE; Czerniak B; Guo CC
Hum Pathol; 2024 Jun; 148():1-6. PubMed ID: 38679207
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ
Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutation in sebaceous neoplasms.
Muñoz-Jiménez MT; Blanco L; Ruano Y; Carrillo R; Santos-Briz Á; Riveiro-Falkenbach E; Requena L; Kutzner H; Garrido MC; Rodríguez-Peralto JL
Virchows Arch; 2021 Sep; 479(3):551-558. PubMed ID: 33768319
[TBL] [Abstract][Full Text] [Related]
9.
Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
[TBL] [Abstract][Full Text] [Related]
10. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
[TBL] [Abstract][Full Text] [Related]
11. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
Roggisch J; Ecke T; Koch S
Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
[TBL] [Abstract][Full Text] [Related]
12. PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates.
Taylor AS; McKenney JK; Osunkoya AO; Chan MP; Al-Ahmadie HA; Spratt DE; Fullen DR; Chinnaiyan AM; Brown NA; Mehra R
Mod Pathol; 2020 Jun; 33(6):1165-1171. PubMed ID: 31932679
[TBL] [Abstract][Full Text] [Related]
13. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Antonelli A
J Clin Pathol; 2022 Jan; 75(1):39-44. PubMed ID: 33144356
[TBL] [Abstract][Full Text] [Related]
14. Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma.
Weyerer V; Weisser R; Moskalev EA; Haller F; Stoehr R; Eckstein M; Zinnall U; Gaisa NT; Compérat E; Perren A; Keck B; Allory Y; Kristiansen G; Wullich B; Agaimy A; Hartmann A; Bertz S
Histopathology; 2019 Dec; 75(6):865-875. PubMed ID: 31348552
[TBL] [Abstract][Full Text] [Related]
15. Brenner tumor associated with rete ovarii: a histologic and immunohistochemical analysis of six cases exploring the relationship between these entities.
Siatecka H; Masand RP
Hum Pathol; 2021 Jul; 113():84-91. PubMed ID: 33812844
[TBL] [Abstract][Full Text] [Related]
16. Brenner Tumor of the Ovary: A 10-Year Single Institution Experience and Comprehensive Review of the Literature.
Alloush F; Bahmad HF; Lutz B; Poppiti R; Recine M; Alghamdi S; Goldenberg LE
Med Sci (Basel); 2023 Feb; 11(1):. PubMed ID: 36810485
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological features of ovarian Brenner tumors].
Zhong PP; Zhu L; Zhang LH; Zheng XZ; Chen TB; Xu F; Zhan Y; Yin CH; Jin YL
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):615-619. PubMed ID: 31422592
[No Abstract] [Full Text] [Related]
18. Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study.
Al-Ezzi EM; Veitch ZW; Salah SH; Van der Kwast TH; Stockley TL; Selvarajah S; Zhang T; Sridhar SS; Sacher AG; Fallah-Rad N; Kulkarni GS; Zlotta AR; Finelli A; Hansen AR
PLoS One; 2021; 16(12):e0259272. PubMed ID: 34851968
[TBL] [Abstract][Full Text] [Related]
19. TERT Promoter Mutation c.-124C>T Commonly Occurs in Low-Grade Fibromatosis-like Metaplastic Breast Carcinoma.
Webersinke G; Burghofer J; Malli T; Rammer M; Jahn SW; Niendorf A; Tavassoli FA; Moinfar F
Arch Pathol Lab Med; 2023 Dec; 147(12):1451-1457. PubMed ID: 36897999
[TBL] [Abstract][Full Text] [Related]
20. A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
Zhang H; Lu X; Huang G; Hua M; Zhang W; Wang T; Huang L; Wang Z; Chen Q; Li J; Yang Q; Yang G
BMC Med Genomics; 2022 Jan; 15(1):1. PubMed ID: 34980126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]